Slide 1: FY23 Results Presentation
Slide 2: Disclaimer
Disclaimer The following provisions apply to this presentation. Please consider its contents carefully. Currency of information The information contained in this presentation is current as at the date of this presentation or such earlier date as specified in this presentation. Summary information Th
Slide 3: Agenda
Agenda O1 Introduction O02 FY23 Snapshot 03 Business Unit Performance 04 Financial Results O05 Summary & Outlook Our Speakers ARI MERVIS CHAIRMAN a SUPRIYA SINGH COMMERCIAL DIRECTOR - ANZ a BRETT CHARLTON CEO & MANAGING DIRECTOR ¥\ JADE PEAK COMMERCIAL DIRECTOR - INTERNATIONAL PAUL WITHERIDGE CFO
Slide 4: Introduction & Welcome
Introduction & Welcome
Slide 5: FY23 Snapshot
FY23 Snapshot
Slide 6: FY23 Overview
FY23 Overview $210.3 (s9.1m | Total SALES REVENUE Owned Underlying GEARING BRAND SALES EBIT DIVIDEND Net Debt: $6.5m FY22: 5.0CPS On FY22: $214.0m On FY22: $11.8m Sales decline of 2%, impactedby de-emphasised private label participation ($8.5m) Multiximpactingoverallsales and profit growth, sales do
Slide 7: Chemist Warehouse
Chemist Warehouse "Steady first year of partnership" Unique, two-way relationship created by the strategic alliance with Chemist Warehouse to deliver benefits to both parties: McPherson’s appointed exclusive distributor for select CWH brands, which are complementary to existing portfolio Provides mu
Slide 8: FY23 Corporate Items
FY23 Corporate Items Material Items — Net $12.0m charge Primary elements for FY23: » Multix non-cash impairment of $8.3m (1H23: $3.9m) + Maseur non-cash impairment of $2.9m (1H23: $0.8m) * Other brand impairments and asset write-downs of $0.5m (1H23: $0.2m) + Professional fees in relation to ASIC ma
Slide 9: Business Unit Performance
Business Unit Performance
Slide 10: ANZ FY23 Highlights
ANZ _ FY23 Highlights FY23 core brand sales vs FY22 Manicare +7.9% & Lady Jayne +25.4% Segment FY23 FY22 Change Change Swisspers +11.8% Performance ($m) ($m) ($m) (%) Fusion Health +10.5% Sales Revenue 200.9 206.1 (5.2) (2.5%) Dr. LeWinns -2.2% A’kin -35.7% Multix -10.5% Underlying EBITDA 20.5 24.5
Slide 11: Growth Tactics
Growth Tactics Integrated ==) Continued marketing a beauty & health campaigns go-to-market model
Slide 12: ANZ - Brand Highlights
ANZ - Brand Highlights Manicare leads innovation in beauty accessories, bringing on-trend beauty tools into the home v > s \ \ KA cal _* : . beatityheayen “eal Lady Jayne elevates at-home hair accessories with premium rechargeable devicesat great value for money Leader in sustainability andinnovatio
Slide 13: ANZ - Brand Highlights
ANZ - Brand Highlights Dr. LeWinn's lead innovation in inner beauty by Fusion continues to expand distribution in launching Australia's first vegan collagen, as pharmacy and launches Mood Support, more Australians move to a plant-based diet responding to increasing focus on mental health ‘AUSTRALIAN
Slide 14: International - FY23 Highlights
International - FY23 Highlights FY23 FY22 Change Change Segment Performance ($m) ($m) ($m) (%) Sales Revenue QS} 7.9 1.4 17.7% Underlying LBITDA (1.3) (2.3) 1.0 43.5% Dr. LeWinn's was impacted by supply constraints in H2 which could not be recovered within the FY, however the brand still delivered 3
Slide 15: International Strategic Imperatives
International Strategic Imperatives International Selective route to structural market through changes driving expert cost optimisation partnerships A’kin brand relaunch in existing markets
Slide 16: Financial Results
Financial Results
Slide 17: Contribution increases and decreases
$ AM $20 Contribution increases $18 $16 $14 $12 Contribution decreases $10 $8 Further commentary on the FY23 results and a reconciliation of underlying to statutory results is provided as Appendices 1 & 2.
Slide 18: 12.0% • 9.9% 10.0% 9.3% • 8.0% 7.2% 6.8% 6.0% 5.5% • 6 9.8
12.0% 12 • 9.9% 10.0% 9.3% 10 • 8.0% 7.2% 6.8% 8 6.0% 5.5% • 6 9.8 9.2 4.0% 4 8.4 7.5 6.5 1.4% 2.0% 2 1.7 0.0% 0 2018 2019 2020 2021 2022 2023 2018 2019 2020 2021 2022 2023
Slide 19: FY23 Dividend
FY23 Dividend - Final ordinary dividend of 1.0 cent per share (cps) fully franked + Payable 22 September 2023 * Total FY23 dividend of 3cps (F22: 5cps) - both fully franked * Consistent with policy to pay a minimum of 60% of underlying profit after tax M MCPHERSON'S
Slide 20: Summary & Outlook
Summary & Outlook
Slide 21: Q&A
Q&A
Slide 22: Thank You
Thank You
Slide 23: Appendices
Appendices
Slide 24: Appendix 1: Further Commentary on Underlying Earnings
Appendix 1: Further Commentary on Underlying Earnings Revenue FY23 ($m) —_- FY22 ($m) Var % Further Commentary Sales revenue 210.3 214.0 AT% Refer detailed presentation (Other income 0.0 0.2 69.4% Total revenue and other income 210.3 214.2 1.8% Underlying Expenses Materials and consumables (108.0) (
Slide 25: Appendix 2: Reconciliation of Underlying to Statutory (LBT)/(PBT)
Appendix 2: Reconciliation of Underlying to Statutory (LBT)/(PBT) Underlying profit before tax Significant items before tax included in statutory (LBT) / PBT Dr. LeWinn’s inventory provision 1.0 (9.4) Multix brand impairment (8.3) 0.0 Other brands impairments and asset write down (3.4) 0.0) Leadersh